What AIO-Studien-gGmbH does

AIO-Studien-gGmbH is a non-profit (gGmbH) academic clinical research organization based in Berlin that provides practical support to oncology investigators in the design, implementation and management of clinical trials in internal oncology. It operates as a subsidiary of the Deutsche Krebsgesellschaft e.V. (German Cancer Society) under the Arbeitsgemeinschaft Internistische Onkologie (AIO), one of the largest scientific working groups within the Society, and serves a community of Prüfärzte (clinical investigators) primarily in Germany with international collaborations.

Its core offering is end-to-end clinical trial coordination — connecting investigators with sponsors and funding, managing projects from conception through completion, providing legal, financial and specialist consultation, and coordinating with international partners and external service providers. The portfolio spans academic clinical trials, non-interventional observational studies, registries (including the CRISP real-world registry 2018–2024), translational laboratory studies, and secondary data use. Sub-products include a study database (Studiendatenbank), a publications repository (Publikationen), and the AIO-Studienakademie training platform. Notable trial outputs include ATOMIC (NEJM, 2026), PREDICT (British Journal of Cancer, 2025), and NintNivo (Lung Cancer, 2026).

Its business model is that of a non-profit professional services CRO: revenue is generated via coordination and sponsorship of clinical trials funded through grants, institutional support from the parent German Cancer Society, and partnerships with pharmaceutical sponsors and international research consortia. There is no traditional product pricing; services are delivered to investigators within the AIO network. The organization does not have external equity funding and does not disclose revenue, reflecting its charitable/public-benefit orientation. An emerging technology initiative — the AI Data Hub piloted with Innoplexus AG / Amrit AG (Partex N.V.) from March 2024 — adds AI-assisted data extraction and analysis on top of the coordination platform.

Name

AIO-Studien-gGmbH

Legal name

AIO-Studien-gGmbH

Website

https://aio-studien-ggmbh.de

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

AIO-Studien-gGmbH is a Berlin-based non-profit academic research organization and subsidiary of the Deutsche Krebsgesellschaft e.V. that coordinates and sponsors clinical trials in internal oncology for investigators within the AIO scientific working group, with growing international collaborations.

Ownership category

akta.pro rank

Product category

Clinical Research Organization Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Engineering, Accounting, Research, Management (8700)

akta.pro primary industry

Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA)

akta.pro secondary industries

Investigator & Site Training / GCP Support (HLAGACAF), Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN), Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)

Keywords

• Clinical trial management
• Academic oncology research
• Investigator-initiated trials
• Clinical research organization
• Oncology study coordination

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Clinical trial sponsorship and coordination services: As a subsidiary of the German Cancer Society, AIO-Studien-gGmbH operates as a non-profit academic research organization. Revenue appears to come from coordinating and sponsoring clinical trials, potentially through grants, institutional funding, and partnerships with pharmaceutical companies and research institutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

AIO-Studien-gGmbH provides practical support to clinical trial investigators (Pruefärzte) in the design, implementation, and management of academic clinical trials in internal oncology. Its team of project managers, coordinators, and study assistants guides research projects from conception through completion, connects investigators with sponsors and funders, and coordinates collaborations with international partners and external service providers. Complementary offerings include the AIO-Studienakademie training program and an AI-supported clinical data processing pilot.

Product overview

AIO-Studien-gGmbH is a not-for-profit organization supporting academic research in internal oncology. The company offers a comprehensive portfolio centered on clinical trial support services, providing practical assistance to physicians in the design, implementation, and management of clinical trial projects. This core offering is complemented by a study database (Studiendatenbank) for tracking clinical studies, a publications repository (Publikationen) for disseminating research findings, and the AIO-Studienakademie for researcher education. The company manages and sponsors numerous clinical studies including the ATOMIC Phase III colon cancer trial, PREDICT pancreatic cancer study, and NintNivo lung cancer study. An emerging technology initiative is the AI Data Hub, a pilot project exploring AI-supported data processing for clinical research applications.

Differentiator

Problem solved

Functional benefit

Brands

• AIO-Studienakademie: An academy/project of AIO-Studien-gGmbH providing training and education in clinical research

Products and services

• Clinical Trial Support Services End-to-end practical support for clinical trial investigators (Pruefärzte) covering study design, implementation, management, legal and financial consultation, and coordination with international partners and external service providers for academic clinical trials in internal oncology.
• AIO-Studienakademie Educational and training program providing professional development for clinical researchers within the AIO network, including retrospective review events (e.g., Rückblick 2025) covering study conduct and methodology.
• AI Data Hub AI-supported data processing service for extracting, structuring, and analyzing clinical care and study data in oncology, developed as a pilot with Innoplexus AG/Amrit AG to enable efficient clinical research.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• AIO (Arbeitsgemeinschaft Internistische Onkologie)coreStrategic or Co-development PartnerAIO-Studien-gGmbH is a subsidiary of the German Cancer Society (Deutsche Krebsgesellschaft e.V.) and works closely with the AIO. The organization coordinates clinical trials and research projects under the AIO umbrella, with AIO representing one of the largest scientific working groups in the German Cancer Society. The partnership involves shared mission of promoting internal oncology through academic research.
• International PartnerscoreStrategic or Co-development PartnerCoordinates collaborations with international partners across multiple clinical trials including the ATOMIC study (Alliance A021502) which involved international Phase III research in colon cancer. Participates in international data pooled analyses.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Parexel International: Global commercial CRO with a dedicated oncology and early-phase practice. Comparable as a clinical trial service provider to biopharma, but operates at vastly larger scale and on a for-profit basis versus AIO-Studien-gGmbH's academic non-profit model.
• WIN Consortium (Worldwide Innovative Network for personalized cancer medicine): Global academic oncology network running translational and biomarker-driven trials. Comparable in academic-cooperative structure and oncology focus, but with a broader international (US/EU) footprint than AIO-Studien-gGmbH's DACH base.
• IQVIA Oncology: Oncology division of one of the largest global commercial CROs. Represents the commercial-CRO counterpoint against which AIO-Studien-gGmbH competes for sponsor-led trials, with greater scale but less academic credibility.

Direct peers

• Charité Research Organisation GmbH: Berlin-based academic research organization affiliated with Charité university hospital, conducting sponsor- and investigator-initiated clinical trials. Comparable geographic and structural profile, though broader in therapeutic area than AIO-Studien-gGmbH.
• EORTC (European Organisation for Research and Treatment of Cancer): European non-profit ARO that designs, coordinates, and conducts clinical trials across multiple tumor types. Most directly comparable to AIO-Studien-gGmbH in mission, structure, and investigator-initiated trial focus, with a similar non-profit academic operating model.
• AGO Research GmbH (Arbeitsgemeinschaft Gynäkologische Onkologie): German oncology ARO focused on gynecological cancers, part of the broader German oncology working-group ecosystem. Comparable as a disease-specific ARO with a society-backed operational company running investigator-initiated trials.
• ETOP (European Thoracic Oncology Platform): European non-profit cooperative group coordinating thoracic oncology trials across multiple countries. Comparable as a network-driven ARO conducting academic-led Phase II/III studies, similar in mission to AIO-Studien-gGmbH.
• IKF Klinische Krebsforschung GmbH (Interdisciplinary Center for Clinical Cancer Research): German oncology-focused clinical research organization coordinating investigator-initiated trials. Operates a similar academic-ARO model with a society-aligned identity, making it a close functional peer in trial sponsorship and coordination.
• German Breast Group (GBG Forschungs GmbH): German non-profit ARO focused on breast cancer clinical trials, operating under a similar gGmbH-style academic research organization model. Directly comparable in country, structure, and IIT-sponsorship mandate, though narrower in tumor-type scope.

Regional players

• Cancer Research UK Clinical Trials Unit: UK-based academic clinical trials unit running oncology IITs. Comparable in mission and academic-ARO model, but serves a different primary geography (UK/National Cancer Research Network) versus AIO-Studien-gGmbH's DACH focus.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Arle-De
• LinkedInlinkedin.com/company/aio-studien-ggmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIO-Studien-gGmbH